Pfizer C440 (Solid Tumors)
What is the Purpose of this Study?
If you choose to join this study, you will:
-Receive injections or infusions of the study drug, once every 2 weeks
-Have a tumor biopsy or provide old tumor tissue
-Provide blood samples
-Have physical exams, blood and urine tests
-Have imaging scans (CT and/or MRI)
-Have heart tests (ECG)
-Receive injections or infusions of the study drug, once every 2 weeks
-Have a tumor biopsy or provide old tumor tissue
-Provide blood samples
-Have physical exams, blood and urine tests
-Have imaging scans (CT and/or MRI)
-Have heart tests (ECG)
What is the Condition Being Studied?
Advanced or metastatic tumors
Who Can Participate in this Study?
Adults with solid tumors, including:
-Non-small cell lung carcinoma (NSCLC)
-Squamous cell carcinoma of the head and neck (SCCHN)
-Ovarian cancer
-Other types of cancer that the study doctor believes may be treated with this drug.
Age Group
Adults
Participating Institutions
What is Involved?
We are doing this study to find out if the study drug is safe and to determine the most effective dose of the study drug.
Study Details
Full Title
A Phase 1 Dose Escalation and Expansion Study Evaluating
the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PF-07257876 in patients with Advanced or Metastatic Tumors
the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PF-07257876 in patients with Advanced or Metastatic Tumors
Principal Investigator
Protocol Number
IRB:
PRO00108555
NCT:
NCT04881045
ClinicalTrials.gov
View on ClinicalTrials.gov